Motor Current Signature Analysis for Pharmaceutical Manufacturing

equipment modifications require change control and validation impact assessments; maintenance activities generate deviation investigations when they affect batch quality. In this environment, equipment failures cause batch deviations, product holds, FDA 483 observations, and consent decree risk. Our current waveform demodulation program specifically targets HVAC air handling units, lyophilizers, tablet presses, centrifuges, clean utility systems (WFI, clean steam), and packaging lines — the assets where early detection has the greatest impact on batch success rate and deviation closure time. We also account for strict change control requirements, adapting our measurement approach to maintain data quality despite these operating conditions.

Yes. Pharmaceutical facilities must comply with FDA 21 CFR Parts 210/211 cGMP, EU Annex 15 qualification, and ISPE GAMP 5 for computerized systems. Our current waveform demodulation program generates the condition documentation needed for cgmp-compliant maintenance documentation with audit trail, equipment qualification records, and calibration traceability. Beyond compliance, the condition data drives measurable improvements in batch success rate and deviation closure time by converting unplanned failures into scheduled repairs. Most pharmaceutical clients see meaningful reductions in batch deviations within the first 12 months of program implementation.

Most of it, yes. Motor Current Signature Analysis measurements at current spectrum sidebands at line frequency ±2× slip frequency are non-intrusive — readings happen at the bearing housing or terminal box without interrupting the equipment. The exceptions are deep diagnostic work that requires de-energization or process isolation, which most Pharmaceutical facilities batch into existing maintenance windows. Routine Motor Current Signature Analysis rounds disrupt nothing.

Top 30 assets ranked by failure consequence, three months of baseline data, then expand based on what the data shows. Trying to cover the full Pharmaceutical equipment population in month one creates noisy data nobody trusts. Tight scope with deep work establishes credibility — that's what gets the budget approved for broader coverage at month four or five.